The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Luc F. Van Gaal

Department of Endocrinology

Diabetology and Metabolism

Antwerp University Hospital

University of Antwerp



Name/email consistency: high



  • Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Belgium. 2001 - 2012


  1. Bariatric surgery to treat type 2 diabetes: what is the recent evidence? Van Gaal, L.F., De Block, C.E. Curr. Opin. Endocrinol. Diabetes. Obes (2012) [Pubmed]
  2. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Van Gaal, L.F., Caterson, I.D., Coutinho, W., Finer, N., Maggioni, A.P., Sharma, A.M., Torp-Pedersen, C., Ge, H., Moran, S.A., Shepherd, G.M., James, W.P. Diabetes. Obes. Metab (2010) [Pubmed]
  3. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Van Gaal, L.F., Scheen, A.J., Rissanen, A.M., Rössner, S., Hanotin, C., Ziegler, O. Eur. Heart J. (2008) [Pubmed]
  4. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Van Gaal, L., Pi-Sunyer, X., Després, J.P., McCarthy, C., Scheen, A. Diabetes. Care (2008) [Pubmed]
  5. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Van Gaal, L.F., Gutkin, S.W., Nauck, M.A. Eur. J. Endocrinol. (2008) [Pubmed]
  6. Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Van Gaal, L. Clin. Cornerstone (2007) [Pubmed]
  7. Mechanisms linking obesity with cardiovascular disease. Van Gaal, L.F., Mertens, I.L., De Block, C.E. Nature (2006) [Pubmed]
  8. New approaches for the management of patients with multiple cardiometabolic risk factors. Van Gaal, L.F., Peiffer, F. J. Endocrinol. Invest. (2006) [Pubmed]
  9. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Van Gaal, L.F. Eur. Neuropsychopharmacol (2006) [Pubmed]
  10. Modern, new pharmacotherapy for obesity. A gastrointestinal approach. Van Gaal, L., Mertens, I., Ballaux, D., Verkade, H.J. Best. Pract. Res. Clin. Gastroenterol (2004) [Pubmed]
  11. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Van Gaal, L.F., De Leeuw, I.H. Diabetologia (2003) [Pubmed]
  12. The importance of obesity in diabetes and its treatment with sibutramine. Van Gaal, L.F., Peiffer, F.W. Int. J. Obes. Relat. Metab. Disord. (2001) [Pubmed]
WikiGenes - Universities